Early Access — free while we kick the tires
EdgarHawk

Wilson Michael Max

Director

Director

Latest: Director selling · May 2026

2 filings analyzed · 1 company · Latest 2026-05-20

Companies

Company Buys Sells Direction
CELESTICA INC CLS 0 3 Net selling

Activity

May 2026
2026-05-20 CELESTICA INC CLS
medium
Sell
4,168 shares
$1,389,236
Significance 6/10

Director Wilson Michael Max sold 4,168 shares of CLS at $333.31 on 2026-05-19 ($1.4M); stock down 20.4% from 52-week high.

Wilson Michael Max (Director) sold 4,168 shares at $333.31, reducing his holdings from 28,886 to 24,718 shares, a 14.4% reduction in position size. The sale occurred near a relative peak in the 52-week cycle, with the stock now trading 20.4% below its 52-week high of $435.00 and down 13.6% over the past 30 days, though up 18.9% over 90 days. His prior sell at this ticker on 2025-01-06 showed a 90-day return of -33.0%, meaning the stock declined after his sale, and his cross-ticker track record includes 1 prior sale with a 90d well-timed rate of 100.00%. The company demonstrates strong fundamentals with $4.0B in quarterly revenue, 28.5% annual growth, and $212.3M net income, though the elevated P/E of 41.54 reflects significant growth expectations already priced in.

January 2025
2025-01-08 CELESTICA INC CLS
high
Sell
25,000 shares
$2,468,250
Significance 6/10

Director Wilson Michael Max sold 25,000 shares of CLS at $98.73 on Jan 6; retains only 1,784 shares (-93.3%).

Director Wilson Michael Max executed a substantial sale of 25,000 shares at $98.73, reducing his stake from 26,784 shares to 1,784 shares, representing a -93.3% reduction in his holdings. The sale occurred near the 52-week high of $102.47, with the stock up 13.3% over the prior 30 days and 67.3% over 90 days. The near-complete exit from a director-level position in a company experiencing significant recent momentum warrants investor attention, as it represents material divestment by an insider rather than modest portfolio adjustment.

Related insiders

Create a free account

Build watchlists, get email alerts on the tickers you follow, and read the full AI analysis on every insider filing.

Sign up — free during early access